I am a nuclear medicine physician with extensive and broad experience in clinical nuclear medicine. I have been practicing nuclear medicine for several years and have been involved in the day-to-day clinical use of radiopharmaceuticals for diagnosis and therapy; and in conducting and interpreting SPECT/CT, PET/CT, and nuclear cardiology studies. I am particularly interested in molecular imaging with PET/CT and in developing novel techniques to diagnose and treat cancer, particularly breast and gynecologic malignancies.
My focus is radiopharmaceutical therapy, and I am studying the use radiolabeled monoclonal antibodies to detect and treat cancers. These include: radiolabeled antibodies 8H9 and 3F8 for pediatric cancers such as metastatic neuroblastoma and brain tumors; radioimmunoPET imaging and radioimmunotherapy for renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, lymphoma, and colon cancer; and the use of peptides in diagnosing and treating neuroendocrine tumors. I am also studying the use of alpha emitters in treating bone metastasis and alpha-emitter-conjugated radiolabeled antibodies in the treatment of other malignancies. I routinely perform radiopharmaceutical therapy with 131I-MIBG for neuroendocrine tumors including neuroblastoma, pheochromocytoma, and paraganglioma; bexxar and zevalin therapy for lymphoma; and strontium or samarium radionuclides to treat metastatic bone disease pain.
I also serve as Director of the Nuclear Medicine Training Program.
- Clinical Expertise: Nuclear Medicine; PET Imaging; Targeted Cancer Therapies
- Awards and Honors: New York Magazine Top Doctors (2012-2016)
- Languages Spoken: English
- Education: MD, Lady Hardinge Medical College (India)
- Residencies: Mount Sinai Medical Center (New York)
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Nuclear Medicine
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Neeta Pandit-Taskar
- A Phase I Study of Intraperitoneal Radioimmunotherapy with 131I-8H9 for Patients with Desmoplastic Small Round Cell Tumors and Other Solid Peritoneal Tumors
- A Phase II Study of Iodine 131-MIBG Alone and with Other Anticancer Drugs in Patients with Recurrent or Persistent Neuroblastoma
- A Pilot Phase II Study of Targeted Radiotherapy with 131I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
- A Pilot Study of PET Imaging of Solid Tumors Using Radioactive Iodine-Labeled Hu3F8
- A Pilot Trial of PET Imaging with (89)Zr-DFO-Trastuzumab in Esophagogastric Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more